Related Experiment Videos
Clarithromycin attenuates cyclophosphamide-induced mucositis in mice
1Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital Compound, Hong Kong, PR China.
Pharmacological Research
|April 8, 2000
Summary
Clarithromycin may reduce chemotherapy-induced mucositis severity in mice, unlike ceftriaxone which may worsen it. Further research in bone marrow transplant recipients is warranted.
Area of Science:
- Oncology
- Pharmacology
- Gastroenterology
Background:
- Mucositis is a debilitating side effect of chemotherapy and chemo-radiotherapy.
- Currently, no universally effective treatment or preventative agent for mucositis exists.
Purpose of the Study:
- To investigate the effect of clarithromycin on cyclophosphamide-induced mucositis in a mouse model.
- To compare clarithromycin's efficacy against normal saline and ceftriaxone in mitigating mucositis.
Main Methods:
- Mice were administered cyclophosphamide to induce mucositis.
- Small intestine sections were collected and histologically graded for mucositis severity.
- Statistical analysis was performed to compare treatment groups.
Main Results:
- Clarithromycin significantly reduced the incidence of mucositis compared to normal saline and ceftriaxone.
- Ceftriaxone showed a trend towards aggravating mucositis compared to normal saline.
- Overall analysis indicated clarithromycin's protective effect against cyclophosphamide-induced mucositis.
Conclusions:
- Clarithromycin may attenuate chemotherapy-induced mucositis.
- Ceftriaxone might exacerbate cyclophosphamide-induced mucositis, suggesting a need for reconsideration in certain clinical contexts.
- Clinical trials in bone marrow transplant recipients are suggested.